News
Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug Wegovy, going down from May’s 21% growth projection to just a 14% sales increase throughout 2025.
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback